New stock news | Danuo Pharmaceuticals submits application to Hong Kong Stock Exchange, owning three core products including Lefortinib (TNP-2198)

According to the Zhixin Financial APP, on July 30, the Hong Kong Stock Exchange disclosed that Danuo Medicine (Suzhou) Co., Ltd. (referred to as Danuo Medicine) has submitted an application for listing on the main board of the Hong Kong Stock Exchange. China Citic Securities and Agricultural Bank International are the joint sponsors.